News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 305
- Sources here
- 19
- Companies here
- 19
Search results
Stored financial headlines
Active search
305 matching headlines
Ticker or company: OLYMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Polyrizon Ltd (PLRZ), detailing future EPS and revenue growth estimates. It includes a snapshot of the company's stock performance, market capitalization, and a peer comparison with other companies in the Biotechnology & Medical Research sector. The content …
PLRZ
main company
Sharemaestro market context
Price below Trend Line
52 weeks +69.4%
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates
Oncolytics Biotech Inc (ONCY) has an earnings forecast score of 7.67, ranking 274 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $5.25 for ONCY, with a high of $10.00 and a low of $3.00, …
ONCY
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.4% · Next-week setup negative 35.3%
Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday
Oncolytics Biotech (ONCY) is scheduled to release its Q2 2026 earnings after market close on Friday, August 14th, with analysts forecasting a loss of $0.0538 per share. The company previously missed consensus estimates, reporting a $0.08-per-share loss. ONCY shares opened at $0.80, and the …
ONCY
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.4% · Next-week setup negative 35.3%
Oncolytics Biotech | 10-Q: Q1 2026 Earnings Report
This article provides the 10-Q report for Oncolytics Biotech for the first quarter of 2026. The content is a placeholder, indicating that the full financial document is intended to be included.
ONCY
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.4% · Next-week setup negative 35.3%
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Oncolytics Biotech Inc (ONCY), stating its current financial score is 6.34 and ranks 258 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is considered stable, though its operating efficiency is …
ONCY
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.4% · Next-week setup negative 35.3%